This week in MathOnco 145
Checkpoint inhibitors, oncolytic viruses, reciprocal cell-cell interactions, tragedy of the commons, metronomic therapy, and more.
“This week in Mathematical Oncology” — Newsletter
Jan. 14, 2021
>
jeffrey.west@moffitt.org
>
From the editor:
Dear readers,
This week’s edition includes articles on checkpoint inhibitors, oncolytic viruses, reciprocal cell-cell interactions, tragedy of the commons, metronomic therapy, and more.
As always, just reply to this email with a link to your publication for consideration to the next edition of the newsletter.
Until next week,
-Jeffrey West
A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden
Joseph D. Butner, Zhihui Wang, Dalia Elganainy, Karine A. Al Feghali, Marija Plodinec, George A. Calin, Prashant Dogra, Sara Nizzero, Javier Ruiz-Ramírez, Geoffrey V. Martin, Hussein A. Tawbi, Caroline Chung, Eugene J. Koay, James W. Welsh, David S. Hong, Vittorio CristiniPolytherapeutic strategies with oncolytic virus–bortezomib and adjuvant NK cells in cancer treatment
Angelica P. Aspirin, Aurelio A. de los Reyes V and Yangjin KimReciprocal interactions between tumour cell populations enhance growth and reduce radiation sensitivity in prostate cancer
Marcin Paczkowski, Warren W. Kretzschmar, Bostjan Markelc, Stanley K. Liu, Leoni A. Kunz-Schughart, Adrian L. Harris, Mike Partridge, Helen M. Byrne & Pavitra Kannan
The Non-Tragedy of the Non-Linear Commons
Marco Archetti, István Scheuring, Douglas YuMetronomic therapy prevents emergence of drug resistance by maintaining the dynamic of intratumor heterogeneity
Maryna Bondarenko, Marion Le Grand, Yuval Shaked, Ziv Raviv, Guillemette Chapuisat, Cecile Carrere, Marie-Pierre Montero, Mailys Rossi, Eddy Pasquier, Manon Carre, Nicolas AndreTumor invasion as non-equilibrium phase separation
Wenying Kang, Jacopo Ferruzzi, Catalina-Paula Spatarelu, Yu Long Han, …, Jin-Ah Park, Ming Guo, Zi Chen, Adrian F. Pegoraro, Jeffrey J. FredbergControl of tumour growth distributions through kinetic methods
L. Preziosi, G. Toscani, M. ZanellaGenealogical structure changes as range expansions transition from pushed to pulled
Gabriel Birzu, Oskar Hallatschek, Kirill S. KorolevLiquidCNA: tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
Eszter Lakatos, Helen Hockings, Maximilian Mossner, Weini Huang, Michelle Lockley, Trevor A Graham
1. Evolutionary Therapy - Request for Application (RFA)
Anticancer Fund: Independent research fund focusing on cancer treatments
Knowledge about tumour evolutionary dynamics has been growing rapidly. However, there has been a limited translation of that knowledge into therapeutic trials. The most clinically advanced strategy is adaptive therapy. Adaptive therapy is a treatment strategy attempting to prolong response to treatment by delaying the emergence of resistance. The goal of adaptive therapy is to maintain a controllable stable tumour burden by allowing a significant population of treatment-sensitive cells to survive. The main principle of the intervention is to control the tumour and prolong survival by allowing on/off treatment periods based on a valid marker.
This RFA will accept clinical trials on adaptive therapy and any other evolutionarily informed strategy, as long as they meet all criteria (see eligibility criteria here).
2. PhysiCell as a Computational Framework of Coordinated Phenotypic Switching in Cancer Metastasis
Lina Sorg: Because cancer is complicated system with many nonlinear agents, its emergence and proliferation continues to plague the public health community. “Cancer turns out to be a really complex systems problem,” Paul Macklin of Indiana University said. “You have processes going on at all different scales, and at the molecular, single-cell, and systems level. […] The goal of a clinician is to tinker with the system and get a better outcome. Our goal as scientists, engineers, and mathematicians is to determine how we can engineer this at the systems level.”
3. Using mathematics to test new approaches to cancer therapy
City University London: “Using mathematical analysis and numerical simulations, [Dr. Noble and Dr. Viossat] established general conditions under which a containment strategy is expected to control tumor burden more effectively than applying the maximum tolerated dose. Importantly, they also identified conditions under which containment might fail to outperform standard of care. Their study was recently accepted for publication; an earlier version is available as a preprint.
Apollo's Arrow:
The Profound and Enduring Impact of Coronavirus on the Way We Live
N. Christakis: "Apollo's Arrow offers a riveting account of the impact of the coronavirus pandemic as it swept through American society in 2020, and of how the recovery will unfold in the coming years. Drawing on momentous (yet dimly remembered) historical epidemics, contemporary analyses, and cutting-edge research from a range of scientific disciplines, bestselling author, physician, sociologist, and public health expert Nicholas A. Christakis explores what it means to live in a time of plague — an experience that is paradoxically uncommon to the vast majority of humans who are alive, yet deeply fundamental to our species."
Understanding the Evolutionary Dynamics and Ecology of Cancer in Treatment Resistance
Guest Editor: David BasantaMathematical Models of Cellular Immunotherapies in Cancer
Guest Editors: V. Pérez-García, L. de Pillis, P. Altrock, R. RockneFrom Ecology to Cancer Biology and Back Again
Guest Editors: Fred Adler, Sarah Amend, Chris WhelanFrontiers in quantitative cancer modeling
Guest Editors: Mohit Kumar Jolly, Heiko Enderling
Postdoc in Statistics & Mathematics for Personalized Breast Cancer Therapy (Alvaro Köhn-Luque)
PhD on Modelling Cell Life and Death (Dan Tennant/Fabian Spill)
Mathematical Modeling Expert in Oncology Translational Science (Boehringer Ingelheim)
Research Associate - Biostatistician (University of Manchester)
Research Fellow in Computational Systems Biology Cancer Research (Simon Mitchell)
Research Fellow in Laboratory and Computational Systems Biology Cancer Research (Simon Mitchell)
Postdoctoral Fellow in Cancer Resistance Modeling, Pfizer (Blerta Shtylla)
Principal Scientist – Oncology PK/PD Modelling (Boehringer Ingelheim)
Postdoctoral Research Position in Computational Immunology (Sylvain Cussat-Blanc)
Postdoc Position - TKI treatments in lung cancer (David Basanta)
Systems Biology Modeler Positions in Biopharma Consulting Company (Helen Moore)
Computational Approaches to Breast Cancer Evolution - Postdoc (Marc Ryser)
Math/statistical models of stem cell lineage dynamics and cancer genomics - Postdoc (Adam MacLean)
Postdoctoral Research Position in Computational Oncology (Tom Yankeelov)
Current subscriber count: 850 mathematical oncologists